Literature DB >> 31538490

Primary sellar melanocytoma: report of two cases treated at the same institution and their long-term outcome.

Luigi Albano1, Marco Losa1, Giorgio Spatola2, Pietro Panni1, Maria Rosa Terreni3, Lina Raffaella Barzaghi1, Pietro Mortini1.   

Abstract

Sellar melanocytomas represent a small subgroup of primary melanocytic tumors arising from leptomeningeal melanocytes. They are benign, slow-growing tumors with a high risk of recurrence. We report two cases of sellar melanocytoma treated at the same institute. A 35-year-old woman presented with amenorrhea and an intrasellar mass with suprasellar extension simulating a hemorrhagic pituitary adenoma. The second case is a 51-year-old man with progressive visual loss and a recurrence of primary sellar and suprasellar melanocytoma. The first patient underwent gross total resection and the second patient underwent subtotal resection. Neither of them was treated with postoperative adjuvant therapies. The second patient had tumor regrowth 75 months after surgery; he therefore underwent gamma knife radiosurgery. Both patients are alive and well at the last follow-up (140 and 93 months, respectively).

Entities:  

Keywords:  Sellar melanocytoma; leptomeningeal melanocytes; pituitary tumor; primary melanocytic brain tumors; transsphenoidal surgery

Year:  2019        PMID: 31538490     DOI: 10.1080/02688697.2019.1667485

Source DB:  PubMed          Journal:  Br J Neurosurg        ISSN: 0268-8697            Impact factor:   1.596


  2 in total

Review 1.  Primary sellar melanocytoma: pathological, clinical and treatment review.

Authors:  L Albano; M Losa; L R Barzaghi; G Spatola; P Panni; M R Terreni; P Mortini
Journal:  J Endocrinol Invest       Date:  2019-12-03       Impact factor: 4.256

2.  Suprasellar Melanocytoma with Leptomeningeal Seeding: An Aggressive Clinical Course for a Histologically Benign Tumor.

Authors:  Imen Maaloul; Marwa Moussaoui; Ameni Salah; Wiem Feki; Hela Fourati; Nadia Charfi; Zeineb Mnif
Journal:  Case Rep Radiol       Date:  2021-10-11
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.